Your browser doesn't support javascript.
loading
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona.
Zanelli, S; Fiorio, E; Zampiva, I; Zacchi, F; Borghesani, G; Giontella, E; Parolin, V; Biondani, P; Zuliani, S; Dieci, M V; Mioranza, E; Zorzi, M; Conti, M; Gibellini, D; Verlato, G; Milella, M.
Afiliación
  • Zanelli S; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Fiorio E; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Zampiva I; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy; Centro Ricerche Cliniche di Verona (CRC), Verona, Italy.
  • Zacchi F; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Borghesani G; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Giontella E; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Parolin V; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Biondani P; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Zuliani S; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Dieci MV; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy; Department of Oncology, Surgery and Gastroenterology, University of Padova, Padua, Italy.
  • Mioranza E; Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy.
  • Zorzi M; Veneto Tumor Registry, Azienda Zero, Padua, Italy.
  • Conti M; Section of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
  • Gibellini D; Department of Diagnostic and Public Health, Microbiology Section, University of Verona, Verona, Italy.
  • Verlato G; Section of Epidemiology and Medical Statistics, Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
  • Milella M; Section of Oncology, Department of Medicine, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy. Electronic address: michele.milella@univr.it.
Ann Oncol ; 33(6): 661-663, 2022 06.
Article en En | MEDLINE | ID: mdl-35276335
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / COVID-19 Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / COVID-19 Tipo de estudio: Diagnostic_studies / Etiology_studies / Risk_factors_studies / Screening_studies Límite: Female / Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido